News

UBS Delivers Impressive 3Q24 Financial Results Amid Challenges

UBS Delivers Impressive 3Q24 Financial Results Amid Challenges

UBS Shows Strong Financial Performance in 3Q24

UBS continues to demonstrate robust financial resilience by announcing its significant financial results for the third quarter of 2024. With a net profit of USD 1.4 billion, this quarter reflects the company’s ability to deliver value to its clients while navigating unprecedented global challenges.

Key Financial Highlights

During 3Q24, UBS reported a profit before tax (PBT) of USD 1.9 billion. The stated underlying profit before tax reached USD 2.4 billion, clearly showcasing the strength of UBS's diversified business model and its well-established client franchises. Furthermore, the group’s return on CET1 capital (RoCET1) stood at 7.6%, with the underlying RoCET1 at a commendable 9.4%.

Growth in Invested Assets

UBS's invested assets reached an impressive USD 6.2 trillion, reflecting a year-on-year increase of 15%. This growth is attributed to continued client momentum and the effective management strategies in place within the Global Wealth Management division, which saw net new assets of approximately USD 25 billion. UBS is on track to achieve its ambitious target of around USD 100 billion in net new assets for the entirety of 2024.

Client Engagement and Transaction Activity

The third quarter also revealed strong transactional activities, particularly in Global Wealth Management and the Investment Bank sectors. Underlying transaction-based income in GWM surged by 19% year-on-year, while revenues from Global Markets surged by 31% in comparison with the continued expansion of client engagement across all regions, notably in the Americas and APAC.

Cost Management and Operational Efficiency

As part of its ongoing commitment to sustainable growth, UBS successfully realized an additional USD 0.8 billion in gross cost savings, with expectations to achieve approximately USD 7.5 billion in total for the full year of 2024. Initiatives to streamline operations and reduce costs exemplify the firm’s strategic emphasis on operational efficiency and disciplined financial management.

Technological Advancements for Future Growth

UBS is also making considerable investments in technology to improve client experiences and efficiency. This includes the rollout of 50,000 Microsoft 365 Copilot licenses, marking the largest deployment in the global financial services industry to date. Such innovations are positioned to enhance service levels and unlock substantial future revenues.

Integration of Credit Suisse: Progress and Outlook

UBS is advancing its integration plans following the acquisition of Credit Suisse. The first wave of client account migrations has been completed, with successful transitions in Luxembourg and Hong Kong. Future migrations are anticipated to take place in Singapore and Japan by the end of this year, with Switzerland planned for 2025.

Maintaining a Strong Capital Position

The firm’s strong capital base supports its strategy and growth ambitions, with CET1 capital ratio recorded at 14.3%. This solid financial grounding remains a critical element of UBS’s performance and strategic direction, as the firm continues to assess and adapt to market conditions.

Frequent Challenges in the Business Environment

The financial landscape remains volatile due to varying geopolitical tensions and market fluctuations. UBS demonstrates its commitment to effectively managing these challenges while focusing on long-term value creation for its stakeholders.

Commitment to Measurable Sustainability Goals

UBS’s ambitions extend beyond financial returns. The firm has reaffirmed its commitment to sustainability by engaging its clients in transitioning to a low-carbon economy and aligning internal operations with sustainable practices. This strategy includes refining operations to meet evolving environmental compliance and expectations.

Frequently Asked Questions

1. What were UBS's net profits in 3Q24?

UBS reported a net profit of USD 1.4 billion for the third quarter of 2024.

2. How much did UBS achieve in net new assets?

UBS achieved approximately USD 25 billion in net new assets within Global Wealth Management during the quarter.

3. What is the expected growth in invested assets for UBS?

UBS's invested assets increased to USD 6.2 trillion, demonstrating a 15% growth year-on-year.

4. How is UBS managing costs effectively?

UBS has realized USD 0.8 billion in cost savings during 3Q24, aiming for a total of approximately USD 7.5 billion for the year.

5. What technological advancements is UBS implementing?

UBS is rolling out 50,000 Microsoft 365 Copilot licenses, positioning itself as an industry leader in technology deployment within financial services.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 342

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading